We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies’ abuse of that provision, key lawmakers say.
The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies’ abuse of that provision, key lawmakers say.
The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies’ abuse of that provision, key lawmakers say.
The HHS’ Office of Inspector General (OIG) is focusing on ways the federal government can reduce the amount it spends for prescription drugs under Medicaid, including greater use of generics, a high-ranking OIG official says.
The HHS’ Office of Inspector General (OIG) is focusing on ways the federal government can reduce the amount it spends for prescription drugs under Medicaid, including greater use of generics, a high-ranking OIG official says.
The HHS’ Office of Inspector General (OIG) is focusing on ways the federal government can reduce the amount it spends for prescription drugs under Medicaid, including greater use of generics, a high-ranking OIG official says.
Federal prosecutors will be more aggressively enforcing anti-kickback laws for deals between industry sales reps and hospitals in Medicaid drug and device negotiations, a high-ranking Department of Justice (DOJ) official said.
The HHS Office of Inspector General’s (OIG) assessment of state qui tam programs will be a hotly debated issue for observers
of a new law providing states with an increased share of Medicaid funds, industry sources say.
Federal prosecutors will be more aggressively enforcing anti-kickback laws for deals between industry sales reps and hospitals in Medicaid drug and device negotiations, a high-ranking Department of Justice (DOJ) official said.
A panel of the Eighth U.S. Circuit Court of Appeals June 22 overturned a ruling in a case where a Missouri policy denied Medicaid device coverage to most of the state’s adult program recipients.